Alzamend Neuro

ALZN

United States· Est. 2008

alzamend.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALZN · Stock Price

USD 1.06-4.86 (-82.10%)

Market Cap: $3.8M

Historical price data

Overview

Alzamend Neuro is a clinical-stage biotech focused on developing novel therapeutics for Alzheimer's disease, bipolar disorder, MDD, and PTSD. Its strategy leverages two licensed technology platforms: an ionic cocrystal for improved lithium delivery (AL001) and a cell-based immunotherapeutic vaccine for Alzheimer's (ALZN002). Key recent achievements include initiating a Phase II trial for AL001 in bipolar disorder with Massachusetts General Hospital and completing a $5 million private placement. The company operates as a lean, development-focused entity targeting significant unmet needs in large patient populations.

Alzheimer's DiseaseBipolar DisorderMajor Depressive DisorderPost-Traumatic Stress Disorder

Technology Platform

Two patented platforms: 1) An ionic cocrystal technology for improved lithium delivery (AL001), and 2) A cell-based mutant-peptide sensitized vaccine for Alzheimer's disease (ALZN002).

Pipeline

3 drugs in pipeline

Drug	Indication	Stage
AL001	Alzheimer's Disease	Phase 1/2
ALZN002 (autologous DCs pulsed with E22W mutant peptide). + ...	Alzheimer Disease	Phase 1/2
AL001 + Lithium Carbonate Capsule	Pharmacokinetics	Phase 1

Funding History

Total raised:$32.5M

PIPE$10MUndisclosedMar 15, 2022

IPO$15MUndisclosedJun 25, 2021

Series A$5MUndisclosedJun 15, 2018

Seed$2.5MUndisclosedJun 15, 2016

Opportunities

A successful reformulation of lithium with a better safety profile could address a multi-billion dollar market across bipolar disorder, MDD, and Alzheimer's, where neuroprotection is sought.

The large, treatment-resistant patient populations provide a significant commercial opportunity if clinical differentiation is proven.

Risk Factors

Extreme clinical development risk inherent in CNS drug trials, heavy reliance on dilutive financing, and intense competition from generic lithium and novel therapies in both neurology and psychiatry.

The company's micro-cap status and volatility add substantial investment risk.

Competitive Landscape

In bipolar disorder/MDD, AL001's primary competitor is generic lithium carbonate; it must prove superior safety. In Alzheimer's, it faces competition from newly approved disease-modifying antibodies and other neuroprotective agents. The cell-based vaccine (ALZN002) enters a high-risk, high-failure segment of the Alzheimer's pipeline.